

A report on the Nomination Committee's work and a reasoned opinion regarding proposals for the election of board member.

In accordance with the principles for the appointment of the Nomination Committee established by the 2019 Annual General Meeting, the four largest shareholders who have accepted the invitation to appoint members of Cellink's Nomination Committee have appointed such members to form the Nomination Committee in the company together with the Chairman of the Board. The Nomination Committee for Cellink thus consists of Rolf Classon (appointed by Erik Gatenholm), Jannis Kitsakis (appointed by the Fourth AP Fund), Malin Björkmo (appointed by Handelsbanken Fonder), Claes Dinkelspiel (appointed by Hector Martinez), and Carsten Browall as Chairman of the Board. The Nomination Committee has appointed Malin Björkmo as chairman.

The Nomination Committee is tasked with preparing proposals for the forthcoming Annual General Meeting in 2021, including the composition of the Board and its remuneration. In light of the fact that the former board member Artur Aira has chosen to take on an operational role in Cellink and therefore left the board on 2 October 2020, however, the nomination committee already wants to submit a proposal regarding the election of a new board member. The most recent Annual General Meeting resolved that the number of Board members be seven. In order to maintain this number and to supplement the current board with relevant competence, the nomination committee proposes that Aristotelis Nastos be elected to the board at an extraordinary general meeting.

The Nomination Committee has so far in its work had one minuted meeting and in addition a number of contacts via e-mail.

The Nomination Committee proposes that the following person be elected to the Board:

Aristotelis Nastos

Dr. Aristotelis Nastos is an experienced venture capitalist working more than 18 years in the field. He is the Head of the Life Science and Cleantech Team at NRW.BANK, managing the

venture capital activities. Before joining NRW.BANK in 2017, he was a Partner for Life Sciences at Creathor Ventures. Before Cellink's acquisition of Scienion AG, he was a board member of Scienion AG.

Aristotelis worked as Research Director at the German Diabetes Research Institute (Duesseldorf) and, as an International Research Fellow of the Wellcome Trust (UK), did his postdoc at the Randal Institute of King's College in London. He holds a PhD in Cell and Developmental Biology from the University Essen and a Master degree in Biology from the Ruhr-University Bochum.

The Nomination Committee assesses that the proposed Board has a composition well adapted to the company's needs and challenges, where each of the members contributes with relevant experience and competence. The Board is characterized by versatility and breadth and has an overall competence that corresponds well to Cellink's operations, development stage and other conditions.

As a diversity policy, the Nomination Committee has applied Rule 4.1 of the Swedish Code of Corporate Governance when preparing its proposal for the election of Board members. The Nomination Committee's proposal to the AGM means that two of the Board's seven members, i.e. 28.6 percent, are women.

The composition of the Board of Directors proposed by the Nomination Committee meets the Swedish Code of Corporate Governance's requirements with regard to independent members.

The Nomination Committee will return for the AGM in 2021 in accordance with the mandate it was given by the AGM in 2020.

Gothenburg in November 2020
CELLINK AB (publ)
The Nomination Committee

